Advertisement
Table 1 Complement activation in plasma from patients with Crohn's disease (CD), patients with ulcerative colitis (UC) and healthy subjects (HS) before and after 1, 6 and 12 weeks high-dose treatment with prednisolone.
| before treatment | after 1 week | after 6 weeks | after 12 weeks | |
|---|---|---|---|---|
| Number of patients | Number of patients | Number of patients | Number of patients | |
| CD | 18 | 18 | 18 | 18 |
| UC | 18 | 18 | 18 | 16 |
| HS | 38 | -- | -- | -- |
| C3-AC, alternative | % of standard | % of standard | % of standard | % of standard |
| CD | 61.5 (53–82) | 51.5 (49–71) | 55.5 (49–70) | 59 (49–75) |
| UC | 58 (49–78) | 49 (49–70) | 49 (49–78) | 59 (49–70) |
| HS | 49 (49–67) | -- | -- | -- |
| C3-AC, classical | % of standard | % of standard | % of standard | % of standard |
| CD | 109 (81–172) | 97.5 (39–124) | 94.5 (70–141) | 99.5 (53–143) |
| UC | 97 (39–148) | 88 (58–129) | 91 (59–115) | 94 (39–160) |
| HS | 82.5 (68–108) | -- | -- | -- |
| MBL-concentration | ng/ml | ng/ml | ng/ml | ng/ml |
| CD | 3251 (14 – 6085) | 3071 (10 – 4636) | 2911 (10 – 5178) | 3257 (10 – 4718) |
| UC | 1082 (6 – 3926) | 1171 (3 – 4845) | 1141 (3 – 4590) | 1292 (3 – 4147) |
| HS | 1219 (2 – 3577) | -- | -- | -- |
| MBL-C4-AC | % of standard | % of standard | % of standard | % of standard |
| CD | 118 (21–187) | 63 (25–192) | 62.5 (21–163) | 87 (17–192) |
| UC | 54 (12–201) | 54 (11–192) | 45 (9–163) | 55 (12–192) |
| HS | 66.5 (9–162) | -- | -- | -- |
